Jefferies has raised its price target on Merck & Co. (NYSE: MRK) to $141 from $138 while maintaining a Buy rating, citing increased conviction in the company’s recent acquisition of Verona Pharma.

Biotech deals originated from China are surging. Takeda touts a pair of OX2R phase 3 wins. Merck's PD-1xVEGF partner is being acquired.

Merck & Co. faces headwinds despite being labeled an undervalued stock. Morgan Stanley recently lowered its price target to $98, maintaining a Hold rating. This decision reflects concerns about the ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing therapies across oncology, immunology, and diabetes and cardiovascular areas ...

An oral version of HIV preexposure prophylaxis (PrEP) that can be taken monthly instead of daily showed good safety and pharmacokinetic characteristics that backed up the monthly dosing, according to ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

Cricket helmets should be made from fiberglass or aluminum to best protect players from head injuries, suggests new research. Protective headgear made from those materials proved more effective ...

Merck KGaA, Darmstadt, Germany recently invited leading representatives from the semiconductor industry to Darmstadt to come together and discuss the role of Germany and Europe in this global industry ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating ...